Danish hearing aid manufacturer Demant raises its 2026 guidance after a strong third quarter, in which organic growth amounted to 11 percent. Revenue increased by 21 percent to DKK 6,624 million.
Organic growth within Hearing Aids amounted to 17 percent, primarily driven by the successful launch of Oticon Reveal, particularly in the US market.
Demant now expects organic growth of 7–8 percent in 2026, compared with the previous 6–7 percent. The forecast for EBIT before special items is raised to DKK 4,700–5,000 million, from the previous DKK 4,400–4,800 million.
At the same time, the company is resuming its share buyback programme and plans to repurchase shares for at least DKK 3 billion through the end of 2027.
